Okay, so everybody’s talking about weight loss drugs. Everybody. Like it’s some new revelation. Eli Lilly, this behemoth, is already raking it in with Mounjaro and Zepbound. Fine. Predictable. But then you have Viking Therapeutics. Viking. It sounds like a Scandinavian furniture company. And now they want to get into the weight loss game? It’s just…a lot. It’s like, can’t we just be happy with what we have? Is everything a competition?
The market is supposed to hit $100 billion. A hundred billion! It’s obscene. And the demand is so high, they can’t even keep up. It’s like toilet paper in 2020 all over again. And now everyone thinks they can just waltz in and grab a piece of the pie. It’s infuriating.
The Lilly Situation
Lilly, they’re the established player. They’ve got the infrastructure, the marketing budget, the whole shebang. They’re already making billions. Billions! And they want more. Of course they do. It’s like, enough is never enough. They’re talking about an oral drug now, orforglipron. An oral drug. As if swallowing a pill is somehow more dignified than an injection. Honestly, the pretension. The sales numbers are good, don’t get me wrong, but it’s all just so…smooth. Too smooth. It feels…calculated. Like they’re deliberately trying to lull you into a false sense of security.
Viking: The Underdog…Maybe
Now Viking. They’re the little guy. They’re still in trials. Phase 2, Phase 3…it’s a whole alphabet soup of uncertainty. But that’s…intriguing, in a way. They haven’t been completely sanitized by corporate bureaucracy yet. They’ve got some cash, over $700 million, which is good. But let’s be real, that’ll disappear faster than you can say “clinical trial failure.” Still, there’s something almost…refreshing about their underdog status. It’s like rooting for the guy who trips and falls but gets back up anyway. Though, admittedly, I’d prefer they didn’t trip in the first place.
The potential is there, sure. If they can get a drug approved, they could carve out a piece of this enormous market. Or they could get swallowed up by a bigger company. Which, frankly, is probably what will happen. It’s the natural order of things. The big fish eat the little fish. It’s depressing, but it’s true.
Million-Dollar Question? More Like a Mildly Annoying Question.
Lilly’s trading at 33 times forward earnings. Thirty-three times! It’s ridiculous. But then again, everything is ridiculous these days. The stock price is already over $1,000. A thousand dollars! It’s just…a lot of money for a pharmaceutical company. It’s hard to see it doubling or tripling from here. It’s like trying to squeeze water from a stone.
Viking, on the other hand, is still a gamble. A risky, potentially rewarding gamble. Their market cap is under $4 billion. That gives them room to run. If they can actually get a drug approved and generate some revenue, they could see significant growth. But it’s a big “if.” A very big “if.” And frankly, I’m tired of “ifs.” I just want certainty. Is that too much to ask?
So, which one is more likely to be a millionaire-maker? Honestly, I don’t know. And frankly, I don’t really care. It’s just…a lot of hype over a problem that people created for themselves in the first place. I need a nap.
Read More
- 39th Developer Notes: 2.5th Anniversary Update
- The 10 Most Beautiful Women in the World for 2026, According to the Golden Ratio
- TON PREDICTION. TON cryptocurrency
- Gold Rate Forecast
- Bitcoin’s Bizarre Ballet: Hyper’s $20M Gamble & Why Your Grandma Will Buy BTC (Spoiler: She Won’t)
- 2025 Crypto Wallets: Secure, Smart, and Surprisingly Simple!
- Nikki Glaser Explains Why She Cut ICE, Trump, and Brad Pitt Jokes From the Golden Globes
- Ephemeral Engines: A Triptych of Tech
- AI Stocks: A Slightly Less Terrifying Investment
- 20 Games With Satisfying Destruction Mechanics
2026-01-26 19:23